Quantcast

Lundbeck study shows Cipralex effective for OCD

November 14, 2005

COPENHAGEN (Reuters) – Danish pharmaceutical group Lundbeck
said on Monday that two Phase III studies had shown its
anti-depressant Cipralex to be effective in treatment of
obsessive-compulsive disorder (OCD).

Cirpralex, sold in the United States as Lexapro by Forest
Laboratories, is approved for the treatment of depression,
panic disorder, social anxiety disorder and generalized anxiety
disorder.

Lundbeck will file for approval of the drug’s use for OCD
in the European Union in the first half of 2006, Lundbeck Vice
President Steen Juul Jensen told Reuters.

“We expect to have a product on the market in the first
half of 2007,” he said.

Forest Laboratories would decide on when to file for
approval in the United States, Juul Jensen said.

OCD is a chronic disorder where the obsessions can be
thoughts that lead to compulsive behavior such as excessive
hand washing or repeating words. OCD patients are estimated to
represent more than ten percent of patients with anxiety
disorders, Lundbeck said.

Shares in Lundbeck were up by 1.1 percent at 142 Danish
crowns at 1547 GMT, while the DJ Stoxx healthcare index was
down 1.0 percent and the Copenhagen blue chip OMXC20 index was
up 0.8 percent.


Source: reuters



comments powered by Disqus